(Total Views: 346)
Posted On: 03/02/2017 8:35:48 AM
Post# of 40524
$RGBP Currently the Company is developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with immunotherapy (dCellVax), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate).
(0)
(0)
Consider all my posts my opinion and not advice to buy or sell anything. I post on stocks I own or am considering owning. Do your own DD!
